Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Osteoarthritis
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Osteoarthritis
    TopAbstracts in Osteoarthritis 11/13/2008 - (DGNews)
    TopAbstracts in Osteoarthritis 10/30/2008 - (DGNews)
    TopAbstracts in Osteoarthritis 10/16/2008 - (DGNews)
    TopAbstracts in Osteoarthritis 10/02/2008 - (DGNews)
    Supplements No Better Than Placebo in Slowing Cartilage Loss in Knees of Osteoarthritis Patients - (DGNews)

    News archive

     Recent webcasts/CME

      Webcasts/CME archive

       Recent cases - Osteoarthritis
        Bullet-Induced Synovitis as a Cause of Secondary Osteoarthritis of the Hip Joint: A Case Report and Review of the Literature
        Infective Discitis Mimicking Infective Endocarditis and Osteoarthritic Back Pain
        An Elderly Man with Weakness and Pain in the Thighs
        An Unusual Pattern of Osteoarthritis of the Fingers in a Nurse

        Cases archive
          




        my personal edition > osteoarthritis > news
        divider

          E-Mail this DGReview to a colleague

        DGReview


        Glucosamine Has Structural/Symptomatic Efficacy while Chondroitin Has Symptomatic Efficacy in Knee Osteoarthritis

        Archives of Internal Medicine

        07/17/2003
        By Elda Hauschildt


        Glucosamine has structural efficacy and both glucosamine and chondroitin have indistinguishable symptomatic efficacies in knee osteoarthritis, according to comprehensive meta-analyses by European researchers.

        Investigators from Belgium and France conducted seven individual, outcome-oriented meta-analyses using 15 randomised clinical trials selected from among approximately 500 studies on the basis of high methodological quality.

        "Our work provides a clear, evidence-based advance regarding the interest in the wide use of glucosamine and chondroitin as disease-modifying compounds in the treatment of knee osteoarthritis through an accurate, conservative analysis of the most reliable experiments performed until now," write researchers led by Dr. Jean-Yves Reginster, from University of Liege, in Liege, Belgium.

        The data covered 1,020 patients who took glucosamine and 755 who took chondroitin.

        The researchers report that quality scores ranged from 60% to 100%, with a mean of 78.4%. Mean quality in the glucosamine trials was 90%, which was significantly higher than the 68.4% in the chondroitin trials.

        "Our data demonstrate efficacy for glucosamine on joint space narrowing and the Western Ontario McMaster University Osteoarthritis Index (WOMAC) and comparable efficacies of chondroitin and glucosamine on the Lequesne Index (LI), visual analogue scale (VAS) for pain and VAS for mobility assessment, in light of the most reliable scientific evidence," they explain. Inclusion criteria for the meta-analyses meant study outcomes had to meet those used by both the United States Food and Drug Administration and the European Agency for Evaluation of Medicinal Products for registering drugs used in treating osteoarthritis.

        All 15 trials were of randomised, double-blind, placebo- controlled, parallel-group prospective design and assessed the structural and/or symptomatic efficacy of oral glucosamine or chondroitin on knee or hip osteoarthritis. The studies were published or performed between January 1980 and March 2002.

        Trials were excluded of either compound was administered intra-articularly or intravenously.

        Individual demographic baselines were well matched in each study. There were no statistical differences for participants on age, sex, body mass index and radiologic score at inclusion. There were also no statistical differences between patients enrolled in glucosamine or chondroitin studies regarding mean age (62.1 years), radiologic score (1.96) or body mass index (27.6).

        Further studies should investigate the relationship among time, dose, patient baseline characteristics and structural efficacy, the investigators write, in order to develop accurate, disease-modifying characteristics of the two compounds.

        They note that both compounds were well tolerated by patients.
        Archives of Internal Medicine 2003;163:1514-1522.

        E-Mail this DGReview to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send